Zeuthen J - Search Results

1

[Interleukin-2 based immunotherapy of cancer].

Geertsen PF, Hermann GG, Claësson MH, Steven K, Zeuthen J, von der Maase H. Geertsen PF, et al. Among authors: zeuthen j. Ugeskr Laeger. 1990 Nov 19;152(47):3513-7. Ugeskr Laeger. 1990. PMID: 2256204 Review. Danish.

2

Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.

Hermann GG, Geertsen PF, von der Maase H, Steven K, Andersen C, Hald T, Zeuthen J. Hermann GG, et al. Among authors: zeuthen j. Cancer Res. 1992 Feb 1;52(3):726-33. Cancer Res. 1992. PMID: 1732060

3

Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma.

Hermann GG, Geertsen PF, von der Maase H, Zeuthen J. Hermann GG, et al. Among authors: zeuthen j. Cancer Immunol Immunother. 1991;34(2):111-4. doi: 10.1007/BF01741344. Cancer Immunol Immunother. 1991. PMID: 1760814 Free PMC article.

4

LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.

Hermann GG, Zeuthen J, Claësson MH. Hermann GG, et al. Among authors: zeuthen j. Nat Immun. 1992 Jan-Feb;11(1):7-16. Nat Immun. 1992. PMID: 1611282

5

Intravesical BCG therapy in bladder carcinoma. Effect on cytotoxicity, IL-2 production and phenotype of peripheral blood mononuclear cells.

Hermann GG, Petersen KR, Zeuthen J, Steven K. Hermann GG, et al. Among authors: zeuthen j. Scand J Urol Nephrol. 1991;25(4):269-73. doi: 10.3109/00365599109024557. Scand J Urol Nephrol. 1991. PMID: 1780700

6

Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.

Hermann GG, Petersen KR, Steven K, Zeuthen J. Hermann GG, et al. Among authors: zeuthen j. J Clin Immunol. 1990 Nov;10(6):311-20. doi: 10.1007/BF00917476. J Clin Immunol. 1990. PMID: 1707414

7

Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.

Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J. Barfoed AM, et al. Among authors: zeuthen j. Scand J Immunol. 2000 Feb;51(2):128-33. doi: 10.1046/j.1365-3083.2000.00668.x. Scand J Immunol. 2000. PMID: 10652158 Free article.

8

Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.

Röpke M, Hald J, Guldberg P, Zeuthen J, Nørgaard L, Fugger L, Svejgaard A, Van der Burg S, Nijman HW, Melief CJ, Claesson MH. Röpke M, et al. Among authors: zeuthen j. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14704-7. doi: 10.1073/pnas.93.25.14704. Proc Natl Acad Sci U S A. 1996. PMID: 8962118 Free PMC article.

9

Transfection of glioma cells with the neural-cell adhesion molecule NCAM: effect on glioma-cell invasion and growth in vivo.

Edvardsen K, Pedersen PH, Bjerkvig R, Hermann GG, Zeuthen J, Laerum OD, Walsh FS, Bock E. Edvardsen K, et al. Among authors: zeuthen j. Int J Cancer. 1994 Jul 1;58(1):116-22. doi: 10.1002/ijc.2910580119. Int J Cancer. 1994. PMID: 8014007

10

[Basic cancer biology].

Danø K, Lund LR, Zeuthen J. Danø K, et al. Among authors: zeuthen j. Ugeskr Laeger. 1989 Jan 2;151(1):45-50. Ugeskr Laeger. 1989. PMID: 2911889 Danish. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page